Valrocemide | TV-1901 | CAS#92262-58-3 | Antiepileptic

Valrocemide
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558300

CAS#: 92262-58-3

Description: Valrocemide, also known as TV-1901, is an antiepileptic drug (AED). Valrocemide has a broad spectrum of anticonvulsant activity and promising potential as a new AED. Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy.

Chemical Structure

Valrocemide

CAS# 92262-58-3

Instruction

Theoretical Analysis

MedKoo Cat#: 558300
Name: Valrocemide
CAS#: 92262-58-3
Chemical Formula: C10H20N2O2
Exact Mass: 200.15
Molecular Weight: 200.282
Elemental Analysis: C, 59.97; H, 10.07; N, 13.99; O, 15.98

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 650
200mg	USD 950
500mg	USD 1650
1g	USD 2250
2g	USD 3850
5g	USD 5750
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Valrocemide; TV-1901; TV 1901; TV1901; SPD-493; TVP-1901; SPD493; TVP1901; SPD 493; TVP 1901;. N-Valproyl glycinamide.

IUPAC/Chemical Name: N-(2-amino-2-oxoethyl)-2-propylpentanamide

InChi Key: RALGCAOVRLYSMA-UHFFFAOYSA-N

InChi Code: InChI=1S/C10H20N2O2/c1-3-5-8(6-4-2)10(14)12-7-9(11)13/h8H,3-7H2,1-2H3,(H2,11,13)(H,12,14)

SMILES Code: CCCC(CCC)C(NCC(N)=O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 200.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Hovinga CA. Valrocemide (Teva/Acorda). Curr Opin Investig Drugs. 2004 Jan;5(1):101-6. Review. PubMed PMID: 14983982.

2: Isoherranen N, Woodhead JH, White HS, Bialer M. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug. Epilepsia. 2001 Jul;42(7):831-6. PubMed PMID: 11488880.

3: Shaltiel G, Mark S, Kofman O, Belmaker RH, Agam G. Effect of valproate derivatives on human brain myo-inositol-1-phosphate (MIP) synthase activity and amphetamine-induced rearing. Pharmacol Rep. 2007 Jul-Aug;59(4):402-7. Erratum in: Pharmacol Rep. 2008 Mar-Apr;60(2):292. Galit, Shaltiel [corrected to Shaltiel, Galit]; Shirley, Mark [corrected to Mark, Shirley]; Ora, Kofman [corrected to Kofman, Ora]; Galila, Agam [corrected to Agam, Galila]. PubMed PMID: 17901568.

4: Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, Jargiełło M, Czuczwar SJ. New generation of valproic acid. Pol J Pharmacol. 2004 May-Jun;56(3):283-8. Review. PubMed PMID: 15215557.

5: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 2004 Sep-Oct;61(1-3):1-48. PubMed PMID: 15570674.

6: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 2002 Sep;51(1-2):31-71. PubMed PMID: 12350382.

7: Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216. Review. PubMed PMID: 19443931.

8: Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. doi: 10.1016/j.eplepsyres.2008.09.005. PubMed PMID: 19008076.

9: Hadad S, Bialer M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm Drug Dispos. 1997 Oct;18(7):557-66. PubMed PMID: 9330777.

10: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 2007 Jan;73(1):1-52. PubMed PMID: 17158031.

11: Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006 Jun;15(6):637-47. Review. PubMed PMID: 16732716.

12: Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006 Jun;69(3):273-94. Review. PubMed PMID: 16621450; PubMed Central PMCID: PMC1562526.

13: Spiegelstein O, Yagen B, Bialer M. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia. 1999 May;40(5):545-52. PubMed PMID: 10386522.

14: Bialer M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J Control Release. 1999 Nov 1;62(1-2):187-92. PubMed PMID: 10518650.

15: Hovinga CA. Novel anticonvulsant medications in development. Expert Opin Investig Drugs. 2002 Oct;11(10):1387-406. Review. PubMed PMID: 12387702.

16: Spiegelstein O, Bialer M, Yagen B. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997 Sep 26;698(1-2):195-200. PubMed PMID: 9367208.

17: Nicolson A, Leach JP. Future prospects for the drug treatment of epilepsy. CNS Drugs. 2001;15(12):955-68. Review. PubMed PMID: 11735615.

18: Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 2001 Jan;43(1):11-58. PubMed PMID: 11137386.

Your view history

Valrocemide featured